These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 7141303)

  • 1. Use of chromogenic peptide substrates in the determination of clotting factors II, VII, IX and X in normal plasma and in plasma of patients treated with oral anticoagulants.
    van Dieijen-Visser MP; van Wersch J; Brombacher PJ; Rosing J; Hemker HC; van Dieijen G
    Haemostasis; 1982; 12(3):241-55. PubMed ID: 7141303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The inhibitor of prothrombin conversion in plasma of patients on oral anticoagulant treatment.
    Bertina RM; Westhoek-Kuipers ME; Alderkamp GH
    Thromb Haemost; 1981 Jun; 45(3):237-41. PubMed ID: 7281102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Further evaluation of an automated amidolytic factor X assay in monitoring anti-vitamin K treatment.
    van Wijk EM; Kahlé LH; Jeletich A; ten Cate JW
    Scand J Haematol; 1982 Aug; 29(2):105-14. PubMed ID: 6813960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chromogenic assays for equine coagulation factors VII, VIII:C, IX, and X, and C1-esterase inhibitor.
    Topper MJ; Prasse KW
    Am J Vet Res; 1998 May; 59(5):538-41. PubMed ID: 9582952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An evaluation of chromogenic substrates in the control of oral anticoagulant therapy.
    Latallo ZS; Thomson JM; Poller L
    Br J Haematol; 1981 Feb; 47(2):307-18. PubMed ID: 7470395
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factor II, VII, IX and X concentrations in patients receiving long term warfarin.
    Paul B; Oxley A; Brigham K; Cox T; Hamilton PJ
    J Clin Pathol; 1987 Jan; 40(1):94-8. PubMed ID: 3818977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The relative importance of the factors II, VII, IX and X for the prothrombinase activity in plasma of orally anticoagulated patients.
    Xi M; Béguin S; Hemker HC
    Thromb Haemost; 1989 Sep; 62(2):788-91. PubMed ID: 2814925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stability of freeze-dried plasma prepared from patients on oral anticoagulants.
    Brozović M; Howarth DJ; van Halem Visser LP; Loeliger EA
    J Clin Pathol; 1973 Nov; 26(11):857-63. PubMed ID: 4797328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of a new chromogenic assay for factor VII and its application in patients on oral anticoagulant treatment.
    Avvisati G; ten Cate JW; van Wijk EM; Kahlé LH; Mariani G
    Br J Haematol; 1980 Jun; 45(2):343-52. PubMed ID: 7437329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma levels of factors II, VII and X and their relationship to the international normalized ratio during chronic warfarin therapy.
    Lind SE; Callas PW; Golden EA; Joyner KA; Ortel TL
    Blood Coagul Fibrinolysis; 1997 Jan; 8(1):48-53. PubMed ID: 9105637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of the hormones of the thyroid axis on the vitamin K-dependent plasma factors of blood coagulation (II, VII, IX, and X).
    Negrev NN; Radev RZ; Velikova MS; Anogeianaki A
    Int J Immunopathol Pharmacol; 2008; 21(1):221-6. PubMed ID: 18336749
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gel filtration properties of factors II, VII, IX, IX a , and X.
    Osterud B; Schiffman S
    Thromb Diath Haemorrh; 1972 Oct; 28(2):317-24. PubMed ID: 4629507
    [No Abstract]   [Full Text] [Related]  

  • 13. Oral anticoagulant therapy and international normalized ratios in swine.
    McGlasson DL; Brickey DA; Doe RH
    Lab Anim Sci; 1998 Aug; 48(4):371-3. PubMed ID: 10090045
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Studies on the prothrombin complex, II. Behavior of prothrombin, factor VII, IX and X during column chromatography on anion exchangesRS].
    Voss D
    Hoppe Seylers Z Physiol Chem; 1967 Sep; 348(9):1172-8. PubMed ID: 5588277
    [No Abstract]   [Full Text] [Related]  

  • 15. Oral anticoagulant control with a chromogenic substrate: calibration, precision and cost.
    Famodu AA; Ingram GI
    Clin Lab Haematol; 1982; 4(1):27-39. PubMed ID: 7067373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence against vitamin K deficiency in normal neonates.
    Malia RG; Preston FE; Mitchell VE
    Thromb Haemost; 1980 Dec; 44(3):159-60. PubMed ID: 7466743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Separation of blood coagulation factors II, VII, IX and X by gel filtration in the presence of dextran blue.
    Swart AC; Hemker HC
    Biochim Biophys Acta; 1970 Dec; 222(3):692-5. PubMed ID: 5496498
    [No Abstract]   [Full Text] [Related]  

  • 18. Circadian rhythms of blood clotting time and coagulation factors II, VII, IX and X in rats.
    Soulban G; Labrecque G
    Life Sci; 1989; 45(25):2485-9. PubMed ID: 2607889
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Determination of blood clotting factor activity in PPSB].
    Tarasova LN; Saltykova ZA
    Vopr Med Khim; 1974; 20(4):440-2. PubMed ID: 4462299
    [No Abstract]   [Full Text] [Related]  

  • 20. An assessment of an amidolytic assay for factor VII in the laboratory control of oral anticoagulants.
    Poller L; Thomson JM; Bodzenta A; Easton AC; Latallo ZS; Chmielewska J
    Br J Haematol; 1981 Sep; 49(1):69-75. PubMed ID: 7272230
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.